Olanzapine Treatment of Female Borderline Personality Disorder Patients: A Double-Blind, Placebo-Controlled Pilot Study
J Clin Psychiatry 2001;62(11):849-854
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The intent of this study was to
compare the efficacy and safety of olanzapine versus placebo in
the treatment of women meeting criteria for borderline
personality disorder (BPD).
Method: We conducted a double-blind,
placebo-controlled study of olanzapine in 28 female subjects
meeting Revised Diagnostic Interview for Borderlines and DSM-IV
criteria for BPD. The subjects were randomly assigned to
olanzapine or placebo in a 2:1 manner. Treatment duration was 6
months. Primary outcome measures were self-reported changes on
anxiety, depression, paranoia, anger/hostility, and interpersonal
sensitivity scales of the Symptom Checklist-90.
Results: Nineteen subjects were randomly
assigned to olanzapine; 9, to placebo. When random effects
regression modeling of panel data was used, controlling for
baseline level of severity, olanzapine was associated with a
significantly (p < .05) greater rate of improvement over time
than placebo in all of the symptom areas studied except
depression. Weight gain was modest in the olanzapine-treated
group but was significantly higher than in those treated with
placebo (p < .02). In addition, no serious movement disorders
Conclusion: Olanzapine appears to be a safe and
effective agent in the treatment of women with criteria-defined
BPD, significantly affecting all 4 core areas of borderline
psychopathology (i.e., affect, cognition, impulsivity, and